Pune based Emcure Pharmaceuticals Ltd. has acquired worldwide rights for BiCNU injection, a is a chemotherapy agent indicated for treatment of brain tumors, multiple myeloma, Hodgkin’s disease and non-Hodgkin’s lymphoma from Bristol-Myers Squibb Company for an undisclosed amount.
The acquisition is expected to increase Emcure’s presence in the global oncology market segment and serve as an anchor product in building the company’s full service oncology franchise.
Commenting on this, Satish Mehta, CEO, Emcure, said, “The acquisition of BiCNUdemonstrates Emcure’s commitment to building a leading franchise in the global oncology market. The BiCNU acquisition coupled with our vertical integration and full line generic oncology pipeline allow us to provide an even wider array of value driven healthcare solutions.”
Under the agreement, Emcure will acquire marketing rights and authorizations, trademarks, and the technology and know-how related to the product. It will acquire all other marketing rights and authorizations held by Bristol-Myers Squibb on a global basis following a transition period during which Bristol-Myers Squibb will continue to distribute the product. Post acquisition, Emcure plans to sell the product through its subsidiaries, including Heritage Pharmaceuticals, Inc. in the United States, and in some cases, through Emcure’s marketing and distribution partners.
Emcure has operations in India, USA, Latin America, Middle East, Africa and other emerging markets with nine manufacturing facilities globally.
